ADHD Patches Recalled

A defective delivery system has prompted Noven Pharmaceuticals Inc to recall a single lot of Daytrana (methylphenidate) patches. The June 1, 2022, US Food and Drug Administration (FDA) Enforcement Report cited customer complaints that “exceeded respective action limits.”

The recall affects Daytrana, 10 mg/9 hours, 30-count cartons (NDC 68968-5552-3), from lot 90764 (Exp. 8/22). The product was distributed throughout the United States.

Noven Pharmaceuticals voluntarily initiated the recall May 6, 2022. On May 20, 2022, the FDA designated the recall Class II. The classification communicates that use of the affected patches could cause temporary or medically reversible adverse health consequences. A remote possibility of serious harm also exists.

Daytrana is a prescription methylphenidate transdermal system indicated for the treatment of attention deficit hyperactivity disorder (ADHD).